Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIN: Neoadjuvant Trastuzumab, Paclitaxel, and Carboplatin in HER2+ Breast Cancer
NCT00768859Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2008
- Primary completion
- Aug 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in HER2-positive breast cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Pathologic Complete Response rate. Started Sep 2008; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00768859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00768859.